ABSTRACT
Background Urinary tract infections (UTIs) are major health concerns affecting millions of people globally each year, and their management is complicated by increasing resistance to antibiotics among uropathogens. Hence, this study was conducted to determine the status of multidrug resistance (MDR) among bacterial uropathogens from symptomatic patients attending tertiary healthcare facilities in Calabar, Nigeria.
Methods A total of 65 uropathogens isolated from symptomatic UTI patients from tertiary healthcare facilities in Calabar were identified using standard microbiological methods. Gram-negative uropathogens were further confirmed with commercial biochemical test kits: Analytical Profile Index (API) 20E and API 20NE (Bio Mérieux). Antibiotic susceptibility of the isolates was determined according to modified Kirby–Bauer method following the Clinical Laboratory Standards Institute recommended guidelines.
Results Klebsiella pneumoniae (23.1%) was the predominant isolate, followed by Staphylococcus sp., (16.9%) and Escherichia coli (12.3%). Other isolates recovered include Enterobacter clocae, Citrobacter freundii, Proteus mirabilis, Serratia marcescens, Pseudomonas aeruginosa, Cronobacter sp., Enterococcus sp., Citrobacter koseri, and Pseudomonas luteola. Most of the isolates were highly resistant to augmentin, amoxicillin, septrin, ampiclox, erythromycin, and rifampicin. However, bacterial strains were sensitive to levofloxacin, gentamicin, ciprofloxacin and sparfloxacin.
Conclusion This research provides an update on the trends in bacterial pathogens causing UTIs, and MDR among uropathogens in different hospitals. This information will assist clinicians in making antibiotic choices in the management of UTIs. To reduce the emergence of resistance in bacterial uropathogens, prudent use of antimicrobial agents is advised.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethical approval for this study was obtained from the Cross River State Health Research Ethics Committee (CRS-HREC) with REC No: CRSMOH/RP/REC/2021/183 and was presented to the administration of UCTH, NNRH and General Hospital Calabar for approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
